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EVIDENCE BASED NEURO-ONCOLOGY
Surgical outcomes of intramedullary spinal cord ependymomas
Ummey Hani,1 Muhammad Waqas Saeed Baqai,2 Muhammad Shahzad Shamim3

Abstract
Intramedullary Spinal Cord Ependymomas (ISCE) are
uncommon pathologies that need to be aggressively
managed before clinical deterioration sets in. Novel
application of different therapeutic strategies is being
assessed for improving long-term outcomes in patients
presenting with these rare neoplasms. In this review, we
have discussed the existing literature on ISCEs, and the
role of surgery in determining outcomes in terms of
neurological status, progression-free survival (PFS) and
overall survival (OS).
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Introduction
Intramedullary spinal cord tumours account for 4-10% of
all primary central nervous system (CNS) neoplasms.1,2
Approximately 60% of all intramedullary neoplasms are
spinal ependymomas, more common in adults than in
children.2,3 The WHO categorizes spinal ependymomas
into 3 histological subtypes: grade I myxopapillary
ependymoma, usually extramedullary; grade II or classic
ependymoma (CE), which includes the cellular, clear cell,
tanycytic, and papillary subtypes; and grade III anaplastic
ependymoma.3-6 Despite demonstrating a relatively
benign course and a usually well-defined dissection plane
in comparison to other intramedullary entities, their
tendency towards recurrence, malignant transformation,
and metastasising along the neuroaxis frequently results
in significant morbidity and mortality.1,7 Herein, we have
reviewed the literature pertaining to the survival
outcomes in patients undergoing treatment for
intramedullary spinal cord ependymomas.

Review of Literature
Ohata et al., published their series of 18 patients who
underwent surgery for intramedullary spinal cord
ependymoma ranging from grade I to III. They achieved
gross total resection (GTR) in 17 patients, while 1 patient,
with a grade II ependymoma, received sub-total resection
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(STR) followed by adjuvant radiotherapy (RT) of 20 Gy.
While there was no surgical mortality, there were either
worsening deficits or new onset deficits in 10 cases:
transient in 7 cases. Follow-up ranged from 10 months to
249 months, with no evidence of clinical or radiological
recurrence. The final neurological outcome was improved
in 1 case, remained unchanged in 15 cases, and worse in
2 cases.8
Oh et al., reviewed 68 studies in 2012, reporting that 268
(77%) out of the 348 total patients with intramedullary
ependymomas received GTR, while the remaining 80
(23%) received STR. Out of the latter, 47 patients also
received RT. The authors demonstrated significantly
lower GTR rates with lower spinal cord ependymomas
and anaplastic pathologies (p = 0.001). A significantly
longer progression free survival (PFS), with an
improvement of 20.2% in the five-year PFS rate, was
reported in patients receiving RT with STR, compared to
those receiving STR alone. The median PFS time was 48
months in the STR group, which was doubled to 96
months with RT. Although more recurrences were
observed in the group with a higher radiation dose (>50
Gy), the results were not statistically significant. However,
improved OS was only associated with GTR and benign
ependymomas, with the five-year overall survival (OS) for
GTR, STR + RT, and STR groups being 98.8%, 79.3%, and
73.7%, respectively.9
In their 20 years’ experience of treating 24 pediatric
patients, Safaee et al., reported similar outcomes between
grade I and grade II lesions with respect to PFS; and extent
of resection was suggested to be the most important
prognostic factor in terms of survival outcomes. A
significantly better PFS was reported in patients with GTR.
Extent of resection was more variable in grade II lesions.
The authors also reported difficulty in achieving GTR in
the upper spinal cord, making tumour location another
significant prognostic factor. There was no immediate or
long-term post-operative mortality.10
Klekamp et al., described their experience with 100
patients with intramedullary ependymomas. In their
series, thoracic ependymomas demonstrated a relatively
worse preoperative clinical course as compared to
cervical tumours. They reported increased risk of
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Figure: a) MRI cervical T1WI spine mid-sagittal sections showing C5-T1 iso-intense lesion; b) T2WI (fat-suppressed) of the same patient showing hyper-intense lesion associated with
syrinx; I) T1WI with contrast showing heterogeneous contrast enhancement.

permanent morbidity with advanced age, thoracic
ependymomas, long clinical history, presence of a tumour
bleed, and surgery on a recurrent lesion. Altogether
86.3% patients underwent GTR, with a low preoperative
McCormick functional classification grade8 and first
surgery was reported as a strong predictor for complete
resection. 67.6% of the patients deteriorated
neurologically in the early postoperative period, with the
deficit being transient for 40.1% of the patients, and
permanent for 27.5%. PFS rates correlated significantly
with extent of resection, with the 20-year recurrence rate
for GTR and STR being 4.2% and 18.5% respectively.
Corresponding OS at 20 years was 92%, with seven deaths
during follow-up. Out of these, 3 were unrelated, 2 were
related to surgery and happened within six weeks postoperatively, one occurred within a year due to postoperative paraplegia-related complications, and 1 was
due to cranial tumours associated with NF-2.1
Lin et al., retrospectively analyzed 64 paediatric patients
with grade II intramedullary ependymomas. 57% of the
subjects underwent GTR. 55 patients were alive at the
median follow-up of 9.2 years, while 9 died at a median of
15 months post-operatively. OS at 5 and 10 years was 86%
and 83%, respectively. In a multivariate regression model
analyzing sex, age at diagnosis, year of diagnosis,
radiotherapy, and extent of resection, female sex was
found to be an independent predictor of decreased
mortality. Tumour progression and recurrence were not
reported in the study.4
Behmanesh et al., published their series of 28 consecutive
patients with intramedullary spinal ependymomas, in
which 25 were WHO grade II, and the rest, grade III. GTR
was achieved in 93% of patients. Four patients had
J Pak Med Assoc

tumour recurrence, for which they underwent second and
third surgeries. While 3 patients experienced minor postoperative complications, there was no mortality within 30
post-operative days. PFS at 5 and 10 was 91% and 85%,
respectively, although OS was not reported. An
interesting observation was the correlation of permanent
unfavourable outcome in 5 out of the 15 (53%) patients,
whose radiology showed spinal cord atrophy at the site of
resection, at the last follow up.2
Svoboda et al., reported 37 patients with intramedullary
ependymomas. Most patients presented with the lesion
in the cervical region, with either a syrinx formation (49%)
or a cyst (32%), seen radiologically. GTR was achieved in
89% of the patients, while 3 patients underwent STR. At a
median follow up of 114 months, PFS was 87%, 82%, and
82% at 5, 10, and 15 years, respectively. OS was 97%, 88%,
and 63% at 5, 10, and 15 years, respectively. The
recurrence rate strongly correlated with the extent of
resection, making GTR the most important factor for PFS.
OS however was more significantly associated with
preoperative clinical status, being significantly better in
patients who had McCormick grades 1 and 2 preoperatively.5
Wostrack et al., reported their multicenter retrospective
experience of 158 adult patients and concluded that GTR
was the most important survival predictor, even with
permanent deficits. GTR was obtained in 80% of the
patients, with 37% showing worsening of neurological
status at discharge. Follow up revealed recovery in
majority, whereas 76% showed at least pre-operative
status. Transient deficits significantly correlated with
cervically located ependymomas and old age. Permanent
deficits, observed in 2% of the patients, were only
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significantly seen in the older patients. Tumour
progression was observed in 15 cases, with the 5-year PFS
being 80%. The PFS of 15 patients who underwent RT
after first surgery was significantly shorter than those who
underwent surgery alone (p < 0.001). However, no
statistically relevant effects of RT, received by 9 patients in
the STR sub-group, were noticed. GTR (p = 0.037), WHO
grade II (p = 0.009), and low Ki-67 index (p = 0.005) were
significant prognostic variables for PFS. The authors did
not report OS in these patients.7

Conclusion
Intramedullary spinal cord ependymomas are rare and
challenging pathologies. While adjuvant radiotherapy
with sub-total resection does prolong progression free
survival, gross total resection remains the cornerstone for
better outcomes. Overall survival, however, mostly
depends upon the pre-operative status and tumour
recurrence. Thus, early and active surgical treatment
aiming at complete tumour removal optimizes long terms
survival outcomes for these patients.

References
1.
2.

Klekamp J. Spinal ependymomas. Part 1: Intramedullary
ependymomas. Neurosurg Focus. 2015;39:E6.
Behmanesh B, Gessler F, Quick-Weller J, Spyrantis A, Imöhl L,

Surgical outcomes of intramedullary spinal cord ependymomas

3.

4.

5.

6.

7.

8.

9.

10.

Seifert V, et al. Regional spinal cord atrophy is associated with
poor outcome after surgery on intramedullary spinal cord
ependymoma: a new aspect of delayed neurological
deterioration. World neurosurg. 2017;100:250-5.
Wild F, Hartmann C, Heissler HE, Hong B, Krauss JK, Nakamura M.
Surgical treatment of spinal ependymomas: Experience in 49
patients. World neurosurg. 2018;111:e703-e9.
Lin Y, Jea A, Melkonian SC, Lam S. Treatment of pediatric Grade II
spinal ependymomas: a population-based study. J NEUROSURGPEDIATR. 2015;15:243-9.
Svoboda N, Bradac O, de Lacy P, Benes V. Intramedullary
ependymoma: long-term outcome after surgery. Acta Neurochir
(Wien). 2018;160(3):439-47.
Wang Y, Cai R, Wang R, Wang C, Chen C. Outcome predictors in
the management of intramedullary classic ependymoma: An
integrative survival analysis. Medicine. 2018;97(23).
Wostrack M, Ringel F, Eicker SO, Jagersberg M, Schaller K,
Kerschbaumer J, et al. Spinal ependymoma in adults: a
multicenter investigation of surgical outcome and progressionfree survival. J Neurosurg - Spine. 2018;28:654-62.
Ohata K, Takami T, Gotou T, El-Bahy K, Morino M, Maeda M, et al.
Surgical outcome of intramedullary spinal cord ependymoma.
Acta Neurochir (Wien). 1999;141:341-6; discussion 6-7.
Oh MC, Ivan ME, Sun MZ, Kaur G, Safaee M, Kim JM, et al.
Adjuvant radiotherapy delays recurrence following subtotal
resection of spinal cord ependymomas. Neuro-oncol.
2013;15:208-15.
Safaee M, Oh MC, Mummaneni PV, Weinstein PR, Ames CP, Chou
D, et al. Surgical outcomes in spinal cord ependymomas and the
importance of extent of resection in children and young adults. J
NEUROSURG-PEDIATR.. 2014;13:393-9.

Vol. 70, No. 10, October 2020

